Partner with us

“We welcome collaborations with academics, clinicians, pharma companies, and CROs who share Curenetics’ goal of improving cancer treatment decisions through our response prediction and translational analytics platform, Cure-io.

We are particularly interested in partnerships that combine high quality clinical and biomarker data to validate and deploy Cure-io in real world workflows, supporting patient stratification, smarter trial design, and faster clinical translation from discovery to impact.”

Contact Us

Smarter patient selection

Safer trials

Faster development

Curenetics partners with pharmaceutical, biotechnology, and clinical research organisations to de-risk immuno-oncology development by improving patient selection, reducing toxicity-related trial attrition, and accelerating clinical decision-making.

At the core of our partnerships is CURE-IO, an AI-driven platform validated in over 5,000 cancer patients. CURE-IO integrates multi-omic, clinical, and tumour microenvironment data to deliver actionable insights that support discovery through late-stage clinical development.

How We Support Our Partners

  • Curenetics supports clinical development teams by strengthening trial readiness and execution, including:

    • Pre-screening for toxicity and response to improve patient selection before enrolment

    • Cohort optimisation to reduce biological noise and improve statistical power

    • Operational efficiency through reduced screen failure and fewer late-stage safety amendments

    • Evidence generation to support internal asset decisions and regulatory-facing narratives

    Sponsor outcomes: more predictable timelines, cleaner endpoints, and improved confidence in programme success.

  • CURE-IO helps CROs deliver more predictable recruitment and stronger sponsor outcomes by:

    • Reducing screen failures through advanced patient stratification

    • Enabling site-agnostic decision support, improving consistency across geographies

    • Supporting biomarker-led and adaptive designs, where stratification is essential

    • Improving data integrity by reducing avoidable protocol deviations driven by toxicity events

    CRO outcomes: improved enrolment performance, reduced operational drag, and a differentiated offering to sponsors.

  • Curenetics provides access to advanced AI capability and translational insight without requiring internal build-out, enabling partners to:

    • Accelerate biomarker discovery and translational programme development

    • Access CURE-IO through platform licensing, bespoke analytics, or white-label integration

    • Strengthen grant applications, investor materials, and regulatory documentation with robust, data-driven insights

    • Leverage Curenetics’ AI expertise and facilities to move faster and reduce cost and execution risk

    Biotech outcomes: faster de-risking, earlier signal clarity, and improved capital efficiency.

Start a Collaboration

If you are looking to improve patient selection, reduce toxicity risk, or strengthen your immuno-oncology pipeline, we would welcome the opportunity to explore a partnership.

  • Curenetics offers flexible engagement models tailored to programme needs, including:

    • Project-based collaborations

    • Platform and data licensing

    • Clinical trial support for sponsors and CROs

    • White-label or embedded AI integrations

    • Strategic consulting and translational advisory services

    This collaborative model enables partners to access Curenetics’ AI expertise, computational infrastructure, and immuno-oncology insight without the burden of building and maintaining complex internal capabilities.

    • AI models validated in 5,000+ patients

    • Access to large-scale genomic and clinical datasets

    • Deep expertise across AI, immuno-oncology, and translational science

    • Proven collaborations across academia, biotech, and pharma

    • A platform designed to support discovery through late-stage development

Contact Us

Regulatory Notice

Curenetics’ platform and analyses are intended to support research and clinical decision-making and do not replace clinical judgement. Regulatory status may vary by geography and intended use.